rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study (CRM)

May 9, 2023 updated by: Medtronic Spinal and Biologics

A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease

The purpose of this study was to evaluate the rhBMP-2/CRM/CD HORIZON® Spinal System as a method of facilitating spinal fusion in patients with degenerative disc disease.

Study Overview

Detailed Description

This clinical trial was conducted to evaluate the rhBMP-2/CRM/CD HORIZON® Spinal System for posterolateral fusion treatment of patients with symptomatic degenerative disc disease versus the control group of autogenous bone with the CD HORIZON® Spinal System.

The investigational treatment was the open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System. One investigational implant was placed across two adjacent transverse processes on each side of the spine during the spinal fusion procedure.

The control treatment was the bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.

Study Type

Interventional

Enrollment (Actual)

463

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arizona
      • Phoenix, Arizona, United States, 85013
        • Barrow Neurosurgical Associates
    • California
      • Orange, California, United States, 92868
        • Orthopaedic Specialty Institute
      • Santa Monica, California, United States, 90404
        • UCLA Orthopedic Hospital
    • District of Columbia
      • Washington, District of Columbia, United States, 20007
        • Georgetown University Dept. of Orthopaedic Spine Surgery
    • Florida
      • Melbourne, Florida, United States, 32901
        • Brevard Orthopaedic Clinic, Inc.
      • Tampa, Florida, United States, 33637
        • Florida Ortho Institute
      • Winter Park, Florida, United States, 32789
        • Florida Neurological Consultants
    • Georgia
      • Columbus, Georgia, United States, 31908
        • The Hughston Clinic P.C.
    • Illinois
      • Hoffman Estates, Illinois, United States, 60195
        • Barrington Orthopedic Specialists
      • Park Ridge, Illinois, United States, 60068
        • Lutheran Spine Center
    • Indiana
      • Carmel, Indiana, United States, 46032
        • The Spine Institute
    • Iowa
      • Iowa City, Iowa, United States, 52241
        • University of Iowa Hospitals & Clinics
      • West Des Moines, Iowa, United States, 50266
        • Des Moines Orthopaedic Surgeons
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Spine Institute
    • Maryland
      • Baltimore, Maryland, United States, 21215
        • Alvin & Lois Lapidus Cancer Insitute
    • Michigan
      • Southfield, Michigan, United States, 48034
        • Jeffrey S. Fischgrund
    • New York
      • Melville, New York, United States, 11747
        • Orthopedic Spine Care of Long Island, PC
      • New York, New York, United States, 10003
        • Beth Israel Medical Center
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke University Hospital
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74136
        • Central States Orthopedic Specialists
    • Oregon
      • Medford, Oregon, United States, 97504
        • Medford Neurological & Spine Clinic
    • Pennsylvania
      • Wyomissing, Pennsylvania, United States, 19610
        • The Reading Neck & Spine Center
    • Tennessee
      • Johnson City, Tennessee, United States, 37604
        • East Tennessee Brain & Spine
    • Texas
      • Fort Worth, Texas, United States, 76104
        • Fort Worth Brain & Spine
      • Plano, Texas, United States, 75093
        • Brain and Spine Center of Texas
      • Tyler, Texas, United States, 75701
        • Azalea Orthopedic & Sports Medicine Clinic
    • Utah
      • Salt Lake City, Utah, United States, 84132
        • University of Utah
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • UVA Dept. of Neurosurgery

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Each patient participating in this clinical trial must meet all of the following inclusion criteria:

  1. Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history of pain and radiographic studies:
  2. Requires fusion of a single level disc space from L1 to S1.
  3. Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of 6 months.
  4. If of child-bearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for 1 year following surgery.

Exclusion Criteria:

A patient meeting any of the following criteria is to be excluded from this clinical trial:

  1. Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade 1 or less spondylolisthesis at the involved level.
  2. Had previous spinal fusion surgical procedure at the involved level.
  3. Requires spinal fusion at more than one lumbar level.
  4. Has been previously diagnosed with osteopenia.
  5. Has presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
  6. Has a history of autoimmune disease (e.g. Systemic Lupus Erythematosus or dermatomyositis).
  7. Has a history of exposure to injectable collagen or silicone implants.
  8. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP 2/CRM implantation.
  9. Has received any previous exposure to any/all BMP's of either human or animal extraction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Investigational
Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.

The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.

The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used.

Other Names:
  • rhBMP-2
  • CRM
  • CD HORIZON® Spinal System
Active Comparator: Control
The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
Other Names:
  • Autograft
  • CD HORIZON® Spinal System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Success
Time Frame: 24 months

A patient will be considered an overall success if all of the following conditions are met:

  1. fusion;
  2. pain/disability (Oswestry) improvement;
  3. maintenance or improvement in neurological status;
  4. no serious adverse event classified as implant associated or implant/surgical procedure associated;
  5. no additional surgical procedure classified as a "failure."
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Loss
Time Frame: At the time of operation
At the time of operation
General Health Status
Time Frame: 24 months

The Medical Outcomes Study 36-item Short Form Health Survey (SF-36) will be used to assess general health status. The SF-36 results can be summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). Success will be defined as a maintenance or improvement in status postoperatively as compared to the preoperative condition. To be classified as a success, the following criteria must be met:

PCSPostop - PCSPreop >= 0; MCSPostop - MCSPreop >= 0

24 months
Operative Time
Time Frame: At the time of operation
At the time of operation
Fusion
Time Frame: 24 months

Fusion is defined as:

  1. Evidence of bridging trabecular bone.
  2. No evidence of motion.
  3. Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass.
24 months
Pain/Disability Status
Time Frame: 24 months
The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success will be defined as pain/disability improvement postoperatively according to the definition: Preoperative Score - Postoperative Score >= 15 points
24 months
Overall Neurological Status
Time Frame: 24 months
Neurological status will be assessed preoperatively and postoperatively using a neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes, and straight leg raise. Overall measure of neurological status will be based on success statuses in the four parameters.
24 months
Back Pain
Time Frame: 24 months

Numerical rating scales will be used to evaluate pain intensity and duration. The pain score (0 min, 20 Max) is derived by adding the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and duration scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Success for back and leg pain is described as follows:

Preoperative Score - Postoperative Score >=0

24 months
Leg Pain
Time Frame: 24 months

Numerical rating scales will be used to evaluate pain intensity and duration. The pain score (0 min, 20 Max) is derived by adding the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and duration scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Success for back and leg pain is described as follows:

Preoperative Score - Postoperative Score >=0

24 months
Hospital Days
Time Frame: At the time of discharge
At the time of discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kenneth Burkus, MD, The Hughston Clinic, P.C.
  • Principal Investigator: John Dimar, MD, Spine Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2002

Primary Completion (Actual)

May 1, 2005

Study Completion (Actual)

February 1, 2010

Study Registration Dates

First Submitted

June 26, 2008

First Submitted That Met QC Criteria

June 27, 2008

First Posted (Estimate)

June 30, 2008

Study Record Updates

Last Update Posted (Actual)

May 10, 2023

Last Update Submitted That Met QC Criteria

May 9, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • P01-05

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe